drugset / Trial / NCT00841126
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate
RandomizedParallel-groupOpen-labelTreatment
Summary
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring hemodialysis, compared with a marketed phosphate binder, lanthanum carbonate and placebo.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fermagate | Unknown | 500 mg | Oral |
| Subject | Fermagate | Unknown | 1000 mg | Oral |
| Comparator | Lanthanum Carbonate | Other / unclassified | 750 mg | Oral |
| Comparator | Lanthanum Carbonate | Other / unclassified | 1500 mg | Oral |